By Sulaksh Editorial Team · Written from the official DU Faculty of Law Sem VIII syllabus (EC 1282) · Reviewed Sept 2026
Every HLP-5 answer is a boardroom memo in disguise. Patent Law and Mergers & Acquisitions — the two anchors of honours cluster HLP-5, flanked by options like IP Law, Business Law, and Law and Technology — do not ask what you feel about deals and monopolies. They ask what number applies, which forum decides, and where the policy fight sits. Honours marking assumes the basics are known; the grade lives in the second paragraph — the tension argued, the position taken, the reform proposed. If your answers stop at definitions, you are writing a pass paper for an honours examiner. This guide keeps you in the second paragraph throughout.
The evergreening wars: Section 3(d) and friends
Start where Indian patent law made world news. The patent bargain — twenty years of exclusivity for full disclosure — is fenced in India by Sections 3 and 4, and the fence with teeth is Section 3(d): new forms of known substances patentable only on proof of enhanced efficacy. Novartis is not optional here; it is the lens through which examiners read every pharma-patent question. Around it, arrange the patentability trinity — novelty, inventive step, industrial application — and the procedural chain students always underprepare: filing, publication, examination, pre-grant representation and post-grant opposition windows, grant, renewal. Procedure gets tested through defects (a blown opposition window, a defective specification, a shaky priority claim), so draw the flowchart once with timelines and rehearse spotting the break. A patentability checklist you can run on any hypothetical invention — novelty, step, utility, exclusions — turns problem questions into form-filling, which is exactly how practitioners do it too.
Licences, access, and the AI inventor who knocked
Rights begin where grant ends: claim construction sets the monopoly's exact width, and infringement — direct and indirect — gets fought with Bolar exemptions, prior-user rights, and government-use defences, ending in injunctions, damages, or accounts. Then the paper's moral centre: compulsory licensing, Natco–Bayer as the landmark, voluntary licences and pools around it, public health emergencies behind all of it. Argue access-versus-incentive with both sides genuinely funded — examiners distinguish priced analysis from slogans instantly, and only the former scores. The frontier unit brings the syllabus's own citation — the Thaler/DABUS inventorship litigation: can a non-human be an inventor? — plus standard-essential patents with FRAND duties and the biologics/data-exclusivity debates. Close every frontier answer with India's calibrated line, incentives balanced with access; that balance has been the paper's thesis since Unit I, and examiners like being reminded you noticed.
Deals as sequences: the M&A machine
Deals are not definitions; they are sequences with consequences. Merger, amalgamation, acquisition, takeover, asset deal, share deal — define each with what follows from the choice (stamp duty, tax, employee transfer, approvals), because consequence-free definitions earn half marks here. India's machinery has three rooms: the Companies Act scheme process (meetings, NCLT sanction), the SEBI Takeover Code (trigger thresholds, open offers, exemptions, competing bids), and CCI combination review (notification, effects, remedies). The most lucrative page in your notes is the thresholds table — offer triggers, creeping limits, delisting numbers, CCI phases — since this paper sets numerical-adjacent questions deliberately. Memorise one Indian deal per type, narratable in four lines; example-backed analysis outscores abstract correctness in every M&A answer I have ever seen marked.
Everyone at the table gets a paragraph
Stakeholder questions fail as omnibus reassurance ("all interests are protected") and pass as party-by-party remedies. Shareholders: exit routes, valuation fights, class rights. Creditors: scheme objections that actually bite. Employees: transfer continuity and compensation. Directors: fiduciary heat in change-of-control, disclosure under light. Regulators: NCLT, SEBI, CCI, RBI on the cross-border leg. Then the practice unit — due diligence red-flag lists, valuation approaches, SPA warranties and indemnities, conditions precedent, closing mechanics — prepared as checklists, because it is examined as checklists ("list the DD flags", "draft the conditions"). Cross-border structure (FEMA pricing, overseas investment routes) is the contemporary garnish; one sketched structure completes any deal answer and signals the Sem-8 student who reads beyond the syllabus.
The options and the referee both converge
Options plug into the anchors with two-page bridges, not fresh preparation. Broader IP: the decision tree — technical core to patents, brand layer to trademarks (with passing-off as the unregistered owner's weapon), creative layer to copyright, look-and-feel to designs — plus one product worked through all four layers. And over everything sits the referee both anchors share: competition law. Patent-side abuse (dominance plus exclusion, FRAND breaches, pools as cartels), M&A-side combinations (market definition, effects, efficiencies, gun-jumping) — prepare one illustration per side, five lines each, and no HLP-5 question lacks its closing competitive-effects paragraph. Which, examiners will tell you over chai if you ask, is the paragraph weighted most.
Two drills: patentability and takeover math
Drill one, patentability. Hypothetical: a crystalline form of a known anti-cancer compound, 30% better bioavailability, full trial data attached. Run the checklist aloud. Novelty: the form is new — pass, provisionally. Inventive step: is the crystalline form obvious to the skilled person, or does the data show unexpected advantage? The data helps; without it, obviousness kills. Industrial application: medicines qualify — pass. Exclusions: Section 3(d) is the entire question — does 30% bioavailability constitute enhanced therapeutic efficacy? Argue Novartis both ways (mere bioavailability versus demonstrated therapeutic gain) and land on the evidence. Procedure: specification sufficiency, opposition windows for rivals to attack. Conclusion follows the checklist; write it last, never first. Drill two, takeover math. Acquirer crosses 25% voting rights in a listed target: open offer triggered for 26% more at a price computed under the regulations (highest of negotiated price, 52-week volume-weighted averages, 60-day high). Creeping limits, competing-offer windows, withdrawal conditions — compute each on sample numbers until thresholds feel like furniture. These two drills, repeated with varying facts, are the numerical soul of HLP-5. Everything else in the cluster is argument; these are arithmetic, and arithmetic does not negotiate.
The second-paragraph workshop
Since honours marks live in the second paragraph, rehearse writing it in isolation. Take any rule and force the tension out: Section 3(d) — access (affordable medicines for millions, the moral weight of health) versus incentive (research costs billions, somebody must fund the next drug) — then India's position (efficacy bar with Novartis as proof of seriousness) and one reform (examination capacity, opposition robustness). Takeover triggers — efficiency (swift control changes, market discipline) versus stakeholder protection (minorities, creditors, employees blindsided) — then India's calibrated thresholds and one reform (timeline compression, disclosure depth). The workshop method: rule at the top of the page, a line down the middle, both sides funded with one case or number each, verdict at the bottom with reasoning attached. Ten such pages, and no HLP-5 question can surprise you, because every question in this cluster is a second paragraph wearing a different rule as a hat. Examiners recognise the workshop graduate within two answers — the reasoning has a shape, and the shape is professional.
Valuation in one paragraph (and why it matters)
Every M&A answer improves the moment valuation stops being a vague noun. Three approaches, one line each: discounted cash flows price the future and argue about the discount rate; comparables price the present through market multiples and argue about the peer set; asset-based floors price the breakup and argue about intangibles. Examiners do not ask you to compute enterprise value to the decimal — they test whether you know which method suits the deal (growth startup versus mature asset-heavy target) and where valuation fights erupt (minority squeeze-outs, dissenting-shareholder exits, tax-authority challenges to slump-sale values). One paragraph naming the method, its fit, and its fight, placed inside any deal answer, signals commercial literacy that pure-law answers lack. Keep a listed-deal valuation controversy in reserve — offer price versus dissenters' claim — and deploy it wherever minority protection arises. Numbers persuade; ranges negotiate; exactness wins.
Do I need a commerce background for M&A? No — and the examiner assumes you don't. Every numerical concept in this paper (thresholds, majorities, waterfall order) is arithmetic plus a defined term, not accountancy. Law students routinely outscore commerce graduates here because the paper grades legal consequences of numbers, not computation speed. Learn what each number triggers and you are fluent.
Deal notes
What separates honours answers from ordinary ones? The second paragraph: tension argued both ways, India's position with a case or deal attached, one reform direction. Rule-only answers cap out early no matter how accurate.
How precise must numbers be? Exact — thresholds, timelines, majorities, with their source section or regulation. In this cluster a wrong number is a wrong answer, while a sourced number carries the whole paragraph.
Where is the official syllabus? DU's course-structure PDF is under DU & College → Others → LLB (Hons) → Semester 1 → Syllabus on Sulaksh. Map every topic to its HLP-5 unit before the exam.